文献速递肾小球疾病

他克莫司联合低剂量激素与高剂量激素治疗成人微小病变肾病疗效与安全性比较

Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.
PubMed 文献 · J Am Soc Nephrol · 2020-11-09

这项24周开放标签非劣效随机研究纳入144例成人微小病变肾病患者,比较他克莫司联合低剂量泼尼松龙与单用高剂量泼尼松龙诱导完全缓解的效果。结果显示两组8周内完全缓解率分别为79.1%和76.8%,达到非劣效;维持期他克莫司联合减量激素组复发率显著更低(5.7% vs 22.6%,P=0.01),安全性无临床相关差异。

要点

  • 他克莫司联合低剂量激素诱导成人微小病变肾病完全缓解非劣于高剂量激素单用。
  • 维持期他克莫司联合减量激素较单用减量激素显著降低复发率。
  • 两组安全性无临床相关差异。

核心结论

  • 他克莫司联合低剂量激素在诱导成人微小病变肾病完全缓解方面非劣于高剂量激素单用。
  • 维持期他克莫司联合减量激素较单用减量激素显著降低复发率,且安全性无临床相关差异。

研究设计与样本

  • 24周开放标签非劣效随机研究,纳入144例成人微小病变肾病患者。
  • 随机分为他克莫司0.05 mg/kg每日两次联合泼尼松龙0.5 mg/kg每日一次组,或泼尼松龙1 mg/kg每日一次单药组,治疗至多8周或至完全缓解。
  • 完全缓解后2周两组激素均减至维持剂量5-7.5 mg/d,直至研究药物启动后24周。

主要发现

  • 8周内完全缓解率:他克莫司联合低剂量激素组53/67例(79.1%),高剂量激素组53/69例(76.8%)。
  • 非劣效性成立:意向性分析置信上限11.6%,符合方案分析置信上限17.0%,均低于预设阈值20%。
  • 两组至缓解时间无显著差异。
  • 维持期他克莫司(3-8 ng/ml)联合减量激素组复发率5.7%,显著低于单用减量激素组的22.6%(P=0.01)。
  • 两组安全性无临床相关差异。

关键数值与推荐

  • 主要终点为8周内完全缓解,定义为尿蛋白肌酐比<0.2 g/g。
  • 次要终点包括至缓解时间和完全缓解后至研究药物启动24周内的复发率(蛋白尿和尿蛋白肌酐比>3.0 g/g)。
  • 他克莫司剂量0.05 mg/kg每日两次,泼尼松龙低剂量0.5 mg/kg每日一次或高剂量1 mg/kg每日一次。
  • 维持期激素剂量5-7.5 mg/d,他克莫司维持血药浓度3-8 ng/ml。

临床怎么用

  • 对于成人微小病变肾病患者,可考虑他克莫司联合低剂量激素作为高剂量激素的替代诱导方案。
  • 维持期使用他克莫司联合减量激素有助于降低复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tacrolimus is used as a steroid-sparing immunosuppressant in adults with minimal change nephrotic syndrome. However, combined treatment with tacrolimus and low-dose steroid has not been compared with high-dose steroid for induction of clinical remission in a large-scale randomized study. METHODS: In this 24-week open-label noninferiority study, we randomized 144 adults with minimal change nephrotic syndrome to receive 0.05 mg/kg twice-daily tacrolimus plus once-daily 0.5 mg/kg prednisolone, or once-daily 1 mg/kg prednisolone alone, for up to 8 weeks or until achieving complete remission. Two weeks after complete remission, we tapered the steroid to a maintenance dose of 5-7.5 mg/d in both groups until 24 weeks after study drug initiation. The primary end point was complete remission within 8 weeks (urine protein: creatinine ratio <0.2 g/g). Secondary end points included time until remission and relapse rates (proteinuria and urine protein: creatinine ratio >3.0 g/g) after complete remission to within 24 weeks of study drug initiation. RESULTS: Complete remission within 8 weeks occurred in 53 of 67 patients (79.1%) receiving tacrolimus and low-dose steroid and 53 of 69 patients (76.8%) receiving high-dose steroid; this difference demonstrated noninferiority, with an upper confidence limit below the predefined threshold (20%) in both intent-to-treat (11.6%) and per-protocol (17.0%) analyses. Groups did not significantly differ in time until remission. Significantly fewer patients relapsed on maintenance tacrolimus (3-8 ng/ml) plus tapered steroid versus tapered steroid alone (5.7% versus 22.6%, respectively; P=0.01). There were no clinically relevant safety differences. CONCLUSIONS: Combined tacrolimus and low-dose steroid was noninferior to high-dose steroid for complete remission induction in adults with minimal change nephrotic syndrome. Relapse rates were significantly lower with maintenance tacrolimus and steroid compared with steroid alone. No clinically-relevant differences in safety findings were observed.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Chin HJ, Chae DW, Kim YC, et al. Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults. J Am Soc Nephrol. 2020. PMID: 33168602. doi:10.1681/ASN.2019050546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。